Medartis Holding Ag · SIX:MED
Medartis — Jefferies Global Healthcare Conference 2025
30 slides from Medartis's conference presentation, Nov 19, 2025
Slide 1: Building on our legacy − growing beyond
Building on our legacy − growing beyond Matthias Schupp, CEO Jefferies Global Healthcare conference, 19 November 2025
Slide 2: Business highlights H1 2025
Business highlights H1 2025 Organic revenue NeoOrtho KeriMedical Guidance growth integration partnership FY 2025 +15.3% CER On plan US entry 14-16% CER − Total sales reached − NeoOrtho integration in − We secured the − Following satisfying trend in CHF 123.0 million, Brazil on plan remaining 53% sta
Slide 3: All segments with double-digit growth
All segments with double-digit growth Sales breakdown by segment (inside) Regional growth in % and H1 2025 organic growth in % (outside) (Organic core sales growth) 20.6 17.8 16.0 16.0 16.2 16.2 16.8% 14.9 14.9 15.3 15.3 13.1 18% H1 2024 8.2 8.2 FY 2024 15.8% H1 2025 67% 3.1 15% 10.3% -9.5 EMEA US A
Slide 4: EBITDA | Core profitability increased thanks to balanced cost management
EBITDA | Core profitability increased thanks to balanced cost management in % of net sales, rounded 21.4 -1.4 − Core EBITDA margin -3.6 +1.4 PP increased +1.4 PP at CER 3.0 0.2 0.0 17.8 -0.8 17.0 − 1.4 PP adverse FX impact 16.4 -1.8 − Balanced OPEX management: Focus on growth investments while keepi
Slide 5: ONE TEAM
ONE TEAM CEO MATTHIAS SCHUPP Executive Management Board KeriMedical Advisory Board Assistant CEO – Board Secretary Cold Fusion Brazil Lead ANTONIETTA FASOLIN DOUGAL BENDJABALLAH & BERNARD PRANDI FREDERICO RINKE COO CFO President US President EMEA CHRO EVP R&D MARIO DELLA CASA DIRK KIRSTEN DAVID THON
Slide 6: From 1 to 5 modern production sites in just 3 years
From 1 to 5 modern production sites in just 3 years Hand prostheses; KeriMedical, Archamps and Besançon, France HQ and premium implant production Basel, Switzerland Premium implants & instruments, US production site, Warsaw, USA Value implants NeoOrtho, Curitiba, Brazil 6
Slide 7: Offsetting US tariff impact
Offsetting US tariff impact ⎼ H1 impact amounted to 0.5 percentage points, reflecting 10% tariffs since April ⎼ Various short-term mitigation actions taken to offset a ~1.2 percentage points impact in H2 ⎼ US production ramp-up to reduce FX exposure and customs impact: • started in late 2024 and acc
Slide 8: Strategic direction: from head to toe
Strategic direction: from head to toe 8
Slide 9: Our Culture: The DNA of Medartis
Our Culture: The DNA of Medartis Agility & Entrepreneurial Decision- Mindset Making IT Promote CUSTOMER Ownership Engagement CENTRICITY Attitude WE I Psychological Passion for Safety Learning
Slide 10: Creating the Medartis Group structure with three distinctive brands
Creating the Medartis Group structure with three distinctive brands Brand Ownership 100% 51% 100% stake
Slide 11: 3 distinctive brands – Go to market depends on market
3 distinctive brands – Go to market depends on market
Slide 12: From head to toe
From head to toe Our legacy Opportunity to become Maintain growth global market leader
Slide 13: Our strategic priorities
Our strategic priorities CUSTOMERS at the centre of what we do 1 2 3 4 5 6 Accelerate US KeriMedical Value Strategy Regional Innovation Improve share gains & Digitalisation Cashflow High-performance culture with a high-performance team
Slide 14: TOUCH is the perfect door opener for our hand & wrist portfolio
TOUCH is the perfect door opener for our hand & wrist portfolio 14
Slide 15: US and Australian market launches in full swing
US and Australian market launches in full swing ⎼ TOUCH rollout in the USA is in progress following FDA approval on 10 July ⎼ US Commercial director appointed, recruited five clinical specialists fully focused on TOUCH rollout ⎼ 45 KOLs in 30 US reference centres have been appointed; the KOLs will b
Slide 16: What are the treatment options?
What are the treatment options? Trapeziectomy with tendon Trapeziectomy interposition + ligament Arthrodesis Arthroplasty reconstruction Images with the curtesey of Dr Arthur Turow 16
Slide 17: CMC-1 arthroplasty is a severely underserved market
CMC-1 arthroplasty is a severely underserved market Penetration of CMC 1 arthroplasty (in % of total surgical treatments) − First prothesis were developed in France in the 70s, Patient pool in thousands elucidating the significant variance in adaptation rates 125 − Up to 15% of the US population >30
Slide 18: KeriMedical has a strong market presence in the markets it serves
KeriMedical has a strong market presence in the markets it serves Estimated market share in selected countries1 − TOUCH has established a strong market presence in 100% EMEA over the past decade 80% − KeriMedical has captured a 70%+ market share in most markets 60% − KeriMedical offers TOUCH in two
Slide 19: We serve 3 segments worth CHF 5-billion with an aspiration to become #1
We serve 3 segments worth CHF 5-billion with an aspiration is to become #1 in upper extremities Market share and growth by segment1 Relative portfolio coverage in upper extremities1 Market share Average market growth orthopeadics 24 20 Hand and Wrist 16 arthroplasty Hand and Wrist 12 fixation 8 Elbo
Slide 20: NeoOrtho acquisition completed in May and integration on plan
NeoOrtho acquisition completed in May and integration on plan Back-office functions consolidation for Medartis Brazil and NeoOrtho scheduled for January HR strategy focuses on retaining key talents and aligning leadership structures New Curitiba production facility targeted for completion in early 2
Slide 21: Appendix
&A medartis 21
Slide 22: Disclaimer
Disclaimer This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve
Slide 23: Upcoming corporate events
Upcoming corporate events Date Event Broker Destination 2025 06 November Swiss Equities conference ZKB Zurich 11 November Healthcare conference Stifel New York 12 November Non-deal roadshow Stifel Chicago 18 November Non-deal roadshow UBS London 19 November Healthcare conference Jefferies London 202
Slide 24: New Outlook 2025
New Outlook 2025 (barring any unforeseen circumstances) ORGANIC1 CORE CORE EBITDA MARGIN (CER) SALES GROWTH 14%-16% High teens range Core Sales Outlook maintained despite additional US tariff headwinds through operating leverage, disciplined cost management and countermeasures 1 "Organic growth" den
Slide 25: Looking back on the first 28 years
Looking back on the first 28 years IBRA Inhouse foundation manufacturing Radial head TriLock SpeedTip arthroplasty technology technology (In2Bones) Head Enter upper Enter Going public at Convertible (Modus) limb (Aptus) lower limb SIX Exchange bond launched 1997 2002 2004 2005 2008 2010 2017 2018 20
Slide 26: Gross margin | Core margin 2.1PP softer primarily due to US tariffs, FX and product mix
Gross margin | Core margin 2.1PP softer primarily due to US tariffs, FX and product mix in % of net sales, rounded -2.1 PP − H1 gross margin 3.0% 82.8 -0.1% -0.8% impacted by FX and new -0.5% US tariffs (each -0.5 PP) -0.4% -0.3% 80.7 -1.2% 80.3 -0.5% − KeriMedical margin 79.5 impact will revert in
Slide 27: EBITDA | Core profitability increased thanks to balanced cost management
EBITDA | Core profitability increased thanks to balanced cost management in % of net sales, rounded 21.4 -1.4 − Core EBITDA margin -3.6 +1.4 PP increased +1.4 PP at CER 3.0 0.2 0.0 17.8 -0.8 17.0 − 1.4 PP adverse FX impact 16.4 -1.8 − Balanced OPEX management: Focus on growth investments while keepi
Slide 28: Net result impacted by FX and financing costs
Net result impacted by FX and financing costs In CHF million -7.7m 0.2 -8.5 − CHF 5m mostly unrealised 0.9 FX losses resulting mainly from decrease of USD and 4.7 7.3 AUD 2.6 − New financing costs after issuance of convertible last year (Keri financing) -0.3 -1.3 -0.9 -0.4 Reported Non-core Core net
Slide 29: Stable cashflow – sufficient cash reserves
Stable cashflow – sufficient cash reserves In CHF million Cash balance − Stable cashflow yoy at year-end − Improved receivables and 127.1 inventory management 120.5 − New set investments in growth markets and fast-moving product categories − Net investment of CHF 14.2 0.6 -1.0 million related to Neo
Slide 30: Analyst coverage: For independent research opinions
Analyst coverage: For independent research opinions Broker Analyst Email Telephone Octavian Sandra Dietschy sandra.dietschy@octavian.ch +41 44 518 08 27 Research Partners AG Ilya Burgansky ilya.burgansky@researchpartners.ch +41 44 533 40 30 Stifel Nicolaus Europe Ltd. Dylan Van Haaften dylan.vanhaaf
Medartis Holding — Jefferies Global Healthcare Conference 2025 on 6ix